Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Coronary Artery Disease: HELP
Articles from Washington
Based on 510 articles published since 2009
||||

These are the 510 published articles about Coronary Artery Disease that originated from Washington during 2009-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline ACR Appropriateness Criteria 2017

Anonymous3940905 / Akers, Scott R / Panchal, Vandan / Ho, Vincent B / Beache, Garth M / Brown, Richard K J / Ghoshhajra, Brian B / Greenberg, S Bruce / Hsu, Joe Y / Kicska, Gregory A / Min, James K / Stillman, Arthur E / Stojanovska, Jadranka / Abbara, Suhny / Jacobs, Jill E. ·Principal Author, VA Medical Center, Philadelphia, Pennsylvania. Electronic address: akerssco@me.com. · Research Author, Internal Medicine Resident, Henry Ford Allegiance Health, Jackson, Michigan. · Panel Vice-Chair, Uniformed Services University of the Health Sciences, Bethesda, Maryland. · University of Louisville School of Medicine, Louisville, Kentucky. · University Hospital, Ann Arbor, Michigan. · Massachusetts General Hospital, Boston, Massachusetts. · Arkansas Children's Hospital, Little Rock, Arkansas. · Kaiser Permanente, Los Angeles, California. · University of Washington, Seattle, Washington. · Cedars Sinai Medical Center, Los Angeles, California; American College of Cardiology. · Emory University Hospital, Atlanta, Georgia. · University of Michigan Health System, Ann Arbor, Michigan. · Specialty Chair, UT Southwestern Medical Center, Dallas, Texas. · Panel Chair, New York University Medical Center, New York, New York. ·J Am Coll Radiol · Pubmed #28473096.

ABSTRACT: In patients with chronic chest pain in the setting of high probability of coronary artery disease (CAD), imaging has major and diverse roles. First, imaging is valuable in determining and documenting the presence, extent, and severity of myocardial ischemia, hibernation, scarring, and/or the presence, site, and severity of obstructive coronary lesions. Second, imaging findings are important in determining the course of management of patients with suspected chronic myocardial ischemia and better defining those patients best suited for medical therapy, angioplasty/stenting, or surgery. Third, imaging is also necessary to determine the long-term prognosis and likely benefit from various therapeutic options by evaluating ventricular function, diastolic relaxation, and end-systolic volume. Imaging studies are also required to demonstrate other abnormalities, such as congenital/acquired coronary anomalies and severe left ventricular hypertrophy, that can produce angina in the absence of symptomatic coronary obstructive disease due to atherosclerosis. Clinical risk assessment is necessary to determine the pretest probability of CAD. Multiple methods are available to categorize patients as low, medium, or high risk for developing CAD. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.

2 Guideline The Society of Thoracic Surgeons Clinical Practice Guidelines on Arterial Conduits for Coronary Artery Bypass Grafting. 2016

Aldea, Gabriel S / Bakaeen, Faisal G / Pal, Jay / Fremes, Stephen / Head, Stuart J / Sabik, Joseph / Rosengart, Todd / Kappetein, A Pieter / Thourani, Vinod H / Firestone, Scott / Mitchell, John D / Anonymous4230852. ·Division of Cardiothoracic Surgery, University of Washington School of Medicine, Seattle, Washington. Electronic address: aldea@uw.edu. · Department of Cardiovascular Surgery, Texas Heart Institute, Houston, Texas. · Division of Cardiothoracic Surgery, University of Washington School of Medicine, Seattle, Washington. · Schulich Heart Centre, Sunnybrook Health Sciences Centre, and Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. · Department of Cardiothoracic Surgery, Erasmus Medical Center, Rotterdam, Netherlands. · Center of Heart Valve Disease, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio. · Department of Surgery, Emory University School of Medicine, Atlanta, Georgia. · The Society of Thoracic Surgeons, Chicago, Illinois. · Department of Surgery, Division of Cardiothoracic Surgery, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado. ·Ann Thorac Surg · Pubmed #26680310.

ABSTRACT: Internal thoracic arteries (ITAs) should be used to bypass the left anterior descending (LAD) artery when bypass of the LAD is indicated (class of recommendation [COR] I, level of evidence [LOE] B). As an adjunct to left internal thoracic artery (LITA), a second arterial graft (right ITA or radial artery [RA]) should be considered in appropriate patients (COR IIa, LOE B). Use of bilateral ITAs (BITAs) should be considered in patients who do not have an excessive risk of sternal complications (COR IIa, LOE B). To reduce the risk of sternal infection with BITA, skeletonized grafts should be considered (COR IIa, LOE B), smoking cessation is recommended (COR I, LOE C), glycemic control should be considered (COR IIa, LOE B), and enhanced sternal stabilization may be considered (COR IIb, LOE C). As an adjunct to LITA to LAD (or in patients with inadequate LITA grafts), use of a RA graft is reasonable when grafting coronary targets with severe stenoses (COR IIa, LOE: B). When RA grafts are used, it is reasonable to use pharmacologic agents to reduce acute intraoperative and perioperative spasm (COR IIa, LOE C). The right gastroepiploic artery may be considered in patients with poor conduit options or as an adjunct to more complete arterial revascularization (COR IIb, LOE B). Use of arterial grafts (specific targets, number, and type) should be a part of the discussion of the heart team in determining the optimal approach for each patient (COR I, LOE C).

3 Editorial Incremental Benefit of CT Perfusion to CT Coronary Angiography: Another Step to the One-Stop-Shop? 2019

Branch, Kelley R. ·Department of Cardiology, University of Washington, Seattle, Washington. Electronic address: kbranch@u.washington.edu. ·JACC Cardiovasc Imaging · Pubmed #29454771.

ABSTRACT: -- No abstract --

4 Editorial Long-term clinical observations for a biofunctionalized stent: Yet to deliver their theoretical benefits. 2018

Nakamura, Kenta / Dean, Larry S. ·Division of Cardiology, Regional Heart Center, University of Washington, Seattle, Washington. · Department of Medicine, Regional Heart Center, University of Washington, Seattle, Washington. ·Catheter Cardiovasc Interv · Pubmed #29894587.

ABSTRACT: Endothelial progenitor cells (EPCs) may allow accelerated and functional endothelialization of stents, theoretically reducing late stent complications as well reducing the duration of DAPT. In a pilot study of 193 patients at high risk of target vessel failure (TVF), the Genous EPC capturing stent (ESC) and TAXUS Liberté paclitaxel-eluting second-generation stent (PES) were similar at 5-years. Events rates appear higher for ESC within the first-year followed by higher rate of complications for PES during years 2-5. A larger randomized multi-center trials powered for non-inferiority of ECS to PES is underway.

5 Editorial The Dye Don't Lie But May Not Tell the Truth: Combining Coronary Computed Tomography Angiography With Myocardial Perfusion Imaging. 2018

Branch, Kelley R / Hamilton-Craig, Christian. ·Division of Cardiology, University of Washington, Seattle, Washington. Electronic address: kbranch@u.washington.edu. · Division of Cardiology, University of Queensland, Brisbane, Australia. ·JACC Cardiovasc Imaging · Pubmed #28823734.

ABSTRACT: -- No abstract --

6 Editorial Incorporating Coronary Artery Calcium Into Global Risk Scoring. 2018

McClelland, Robyn L / Blaha, Michael J. ·Department of Biostatistics, University of Washington, Seattle, Washington. Electronic address: rmcclell@uw.edu. · Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, Maryland. ·JACC Cardiovasc Imaging · Pubmed #28624403.

ABSTRACT: -- No abstract --

7 Editorial Epicardial adipose tissue-Truly at the heart of the coronaries? 2016

Phan, Binh An P / Bahrainy, Samira / Gill, Edward A. ·Division of Cardiology, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, CA, USA. · Department of Emergency Medicine, VA Medical Center Puget Sound, Seattle, WA, USA; Harborview Medical Center, Seattle, WA, USA. · Division of Cardiology, Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA. Electronic address: eagill@u.washington.edu. ·J Clin Lipidol · Pubmed #27206933.

ABSTRACT: -- No abstract --

8 Editorial Spectral response in reversing coronary artery atherosclerosis with vitamin D supplementation in postmenopausal cynomolgus monkeys. 2016

Pru, James K. ·Center for Reproductive Biology, Washington State University, Pullman, WA. ·Menopause · Pubmed #27045701.

ABSTRACT: -- No abstract --

9 Editorial SCAI position statement concerning coverage policies for percutaneous coronary interventions based on the appropriate use criteria. 2016

Klein, Lloyd W / Blankenship, James C / Kolansky, Daniel M / Dean, Larry S / Naidu, Srihari S / Chambers, Charles E / Duffy, Peter L / Anonymous2810861. ·Rush Medical College, Chicago, IL. · Geisinger Medical Center, Danville, PA. · University of Pennsylvania School of Medicine, Philadelphia, PA. · University of Washington, Seattle, WA. · Winthrop University Hospital, Mineola, NY. · Hershey Medical Center, Hershey, PA. · FirstHealth of the Carolinas, Reid Heart Center, Pinehurst, NC. ·Catheter Cardiovasc Interv · Pubmed #26968441.

ABSTRACT: -- No abstract --

10 Editorial Heart-type fatty acid-binding protein (H-FABP) and coronary heart disease. 2016

Das, Undurti N. ·UND Life Sciences, 2020 S 360th St, # K-202, Federal Way, WA 98003, USA. Electronic address: undurti@lipidworld.com. ·Indian Heart J · Pubmed #26896261.

ABSTRACT: -- No abstract --

11 Editorial Insulin resistance and in-stent restenosis: could modulating insulin improve outcomes of percutaneous coronary intervention? 2015

Armstrong, Ehrin J / McCabe, James M. ·aVA Eastern Colorado Healthcare System, Division of Cardiology, Department of Medicine, University of Colorado School of Medicine, Denver, Colorado bDivision of Cardiology, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA. ·Coron Artery Dis · Pubmed #25489860.

ABSTRACT: -- No abstract --

12 Editorial Coronary involvement in lupus patients: getting sharper pictures with advanced vascular imaging? 2014

Sun, Jie / Yuan, Chun. ·Department of Radiology, University of Washington, Seattle, Washington. · Department of Radiology, University of Washington, Seattle, Washington; Department of Bioengineering, University of Washington, Seattle, Washington. Electronic address: cyuan@uw.edu. ·JACC Cardiovasc Imaging · Pubmed #25124008.

ABSTRACT: -- No abstract --

13 Editorial β-blockers for secondary prevention in stable coronary artery disease: can observational studies provide valid answers? 2014

Floyd, James S. ·Cardiovascular Health Research Unit, University of Washington, Seattle, Washington, USA Department of Medicine, University of Washington, Seattle, Washington, USA. ·Heart · Pubmed #25060756.

ABSTRACT: -- No abstract --

14 Editorial Continuous positive airway pressure in cardiovascular medicine: the underlying physiology is frequently unknown. 2014

Agostoni, Piergiuseppe / Contini, Mauro / Sciomer, Susanna / Palermo, Pietro / Sisillo, Erminio. ·aCentro Cardiologico Monzino, IRCCS bDepartment of Clinical Sciences and Community Health, Cardiovascular Section, University of Milano, Milano, Italy cDivision of Pulmonary and Critical Care and Medicine, Department of Medicine, University of Washington, Seattle, Washington, USA dDepartment of Cardiovascular and Respiratory Sciences, 'La Sapienza' University, Rome, Italy. ·J Cardiovasc Med (Hagerstown) · Pubmed #24751479.

ABSTRACT: -- No abstract --

15 Editorial Progress: the ROPAC multinational registry advances our understanding of an important outcome in pregnant women with heart disease. 2014

Krieger, Eric V / Stout, Karen K. ·Division of Cardiology, Department of Medicine, University of Washington Medical Center, University of Washington School of Medicine, , Seattle, Washington, USA. ·Heart · Pubmed #24293522.

ABSTRACT: -- No abstract --

16 Review Role of Coronary Calcium Score to Identify Candidates for ASCVD Prevention. 2019

Nguyen, Hong Loan / Liu, Jing / Del Castillo, Maygen / Shah, Tina. ·Baylor College of Medicine, McNair Campus, 7200 Cambridge St., Suite 8B, Houston, TX, 77030, USA. · Baylor College of Medicine, 6620 Main St., Houston, TX, 77030, USA. · Baylor College of Medicine, McNair Campus, 7200 Cambridge St., Suite 8B, Houston, TX, 77030, USA. Jing.Liu@bcm.edu. · Baylor College of Medicine, 6620 Main St., Houston, TX, 77030, USA. Jing.Liu@bcm.edu. · Kaiser Permanente, Capitol Hill Medical Center, Seattle, USA. ·Curr Atheroscler Rep · Pubmed #31754800.

ABSTRACT: PURPOSE OF REVIEW: In this review, we describe the mechanism behind coronary artery calcification formation and detection, as well as its implication in cardiovascular disease (CVD) risk stratification, intervention, and prognosis in asymptomatic individuals. RECENT FINDINGS: Multiple cohort and population studies have shown that coronary artery calcium scoring is effective and reproducible in predicting the risk for cardiovascular disease. The updated 2018 ACC/AHA guideline has incorporated consideration of coronary artery calcification testing into cardiovascular disease risk stratification and therapy guidance. Coronary artery calcification's evidence-based role in detection, risk stratification, and ultimately its unique influence on therapeutic intervention and prognosis of cardiovascular disease in asymptomatic population is increasingly being recognized..

17 Review Effect of increasing age on percutaneous coronary intervention vs coronary artery bypass grafting in older adults with unprotected left main coronary artery disease: A meta-analysis and meta-regression. 2019

Khan, Mahin R / Kayani, Waleed T / Ahmad, Waqas / Manan, Malalai / Hira, Ravi S / Hamzeh, Ihab / Jneid, Hani / Virani, Salim S / Kleiman, Neal / Lakkis, Nasser / Alam, Mahboob. ·Division of Cardiology, McLaren-Flint/Michigan State University, Flint, Michigan. · Section of Cardiology, Department of Internal Medicine, Baylor College of Medicine, Houston, Texas. · Department of Internal Medicine, Nishtar Medical University, Multan, Pakistan. · Department of Internal Medicine, King Edward Medical University, Lahore, Pakistan. · Division of Cardiology, University of Washington, Seattle, Washington. · Section of Cardiology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas. · Houston Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, Texas. ·Clin Cardiol · Pubmed #31486094.

ABSTRACT: BACKGROUND: Older adults (≥70-year-old) are under-represented in the published data pertaining to unprotected left main coronary artery disease (ULMCAD). HYPOTHESIS: Percutaneous coronary intervention (PCI) might be comparable to coronary artery bypass grafting (CABG) for revascularization of ULMCAD. METHODS: We compared PCI versus CABG in older adults with ULMCAD with an aggregate data meta-analyses (4880 patients) of clinical outcomes [all-cause mortality, myocardial infarction (MI), repeat revascularization, stroke and major adverse cardiac and cerebrovascular events(MACCE)] at 30 days, 12-24 months & ≥36 months in patients with mean age ≥70 years and ULMCAD. A meta-regression analysis evaluated the effect of age on mortality after PCI. Odds ratios (OR) and 95% confidence intervals (CI) were estimated using random-effects model. RESULTS: All-cause mortality between PCI and CABG was comparable at 30-days (OR0.77, 95% CI 0.42- 1.41) and 12-24-months (OR 1.22, 95% CI 0.78-1.93). PCI was associated with a markedly lower rate of stroke at 30-day follow-up in octogenarians (OR 0.14, 95% CI 0.02-0.76) but an overall higher rate of repeat revascularization. At ≥36-months, MACCE (OR 1.26,95% CI 0.99-1.60) and all-cause mortality (OR 1.39, 95% CI 1.00-1.93) showed a trend favoring CABG but did not reach statistical significance. On meta-regression, PCI was associated with a higher mortality with advancing age (coefficient=0.1033, p=0.042). CONCLUSIONS: PCI was associated with a markedly lower rate of early stroke in octogenarians as compared to CABG. All-cause mortality was comparable between the two arms with a trend favoring CABG at ≥36-months.PCI was however associated with increasing mortality with advancing age as compared to CABG.

18 Review Sex-Based Differences in Chronic Total Occlusion Management. 2018

Cheney, Amy / Kearney, Kathleen E / Lombardi, William. ·Division of Cardiology, University of Washington, Seattle, WA, USA. aec1@cardiology.washington.edu. · Division of Cardiology, University of Washington, Seattle, WA, USA. ·Curr Atheroscler Rep · Pubmed #30406420.

ABSTRACT: ᅟ: Chronic total occlusions (CTOs) are an important and increasingly recognized subgroup of coronary lesions, documented in at least 30%, but up to 52% of patients with coronary artery disease (CAD) undergoing coronary angiography. Percutaneous coronary intervention (PCI) of these lesions is increasingly pursued, with excellent success rates. PURPOSE OF REVIEW: It is known that gender differences exist in the presentation of CAD, as well as in clinical outcomes after routine PCI; however, it is not well described how these differences pertain to management of CTOs. This review summarizes the available data regarding sex-based differences in CTO management and outcomes. RECENT FINDINGS: Women comprise approximately 20% of CTO registry and trial participants. As has been demonstrated in PCI studies, women comprise a minority of patients in CTO PCI registries and trials. Sex-based differences exist in complication rates, collateral formation, and outcomes and need further evaluation in future studies.

19 Review Myocardial Assessment with Cardiac CT: Ischemic Heart Disease and Beyond. 2018

Ramsey, Bryan C / Fentanes, Emilio / Choi, Andrew D / Branch, Kelley R / Thomas, Dustin M. ·1Cardiology Division, Department of Medicine, San Antonio Military Medical Center, San Antonio, TX USA. · 0000 0004 0450 5663 · grid.416653.3 · 2Cardiology Division, Department of Medicine, Tripler Army Medical Center, Honolulu, HI USA. · 0000 0004 0474 295X · grid.417301.0 · 3Division of Cardiology, Department of Radiology, The George Washington University School of Medicine, Washington, DC USA. · 0000 0004 1936 9510 · grid.253615.6 · 4Cardiology Division, University of Washington, Seattle, WA USA. · 0000000122986657 · grid.34477.33 ·Curr Cardiovasc Imaging Rep · Pubmed #29963220.

ABSTRACT: Purpose of Review: The aim of this review is to highlight recent advancements, current trends, and the expanding role for cardiac CT (CCT) in the evaluation of ischemic heart disease, nonischemic cardiomyopathies, and some specific congenital myocardial disease states. Recent Findings: CCT is a highly versatile imaging modality for the assessment of numerous cardiovascular disease states. Coronary CT angiography (CCTA) is now a well-established first-line imaging modality for the exclusion of significant coronary artery disease (CAD); however, CCTA has modest positive predictive value and specificity for diagnosing obstructive CAD in addition to limited capability to evaluate myocardial tissue characteristics. Summary: CTP, when combined with CCTA, presents the potential for full functional and anatomic assessment with a single modality. CCT is a useful adjunct in select patients to both TTE and CMR in the evaluation of ventricular volumes and systolic function. Newer applications, such as dynamic CTP and DECT, are promising diagnostic tools offering the possibility of more quantitative assessment of ischemia. The superior spatial resolution and volumetric acquisition of CCT has an important role in the diagnosis of other nonischemic causes of cardiomyopathies.

20 Review Cardiovascular Disease in Survivors of Childhood Cancer: Insights Into Epidemiology, Pathophysiology, and Prevention. 2018

Armenian, Saro H / Armstrong, Gregory T / Aune, Gregory / Chow, Eric J / Ehrhardt, Matthew J / Ky, Bonnie / Moslehi, Javid / Mulrooney, Daniel A / Nathan, Paul C / Ryan, Thomas D / van der Pal, Helena J / van Dalen, Elvira C / Kremer, Leontien C M. ·Saro H. Armenian, City of Hope, Duarte, CA · Gregory T. Armstrong, Matthew J. Ehrhardt, and Daniel A. Mulrooney, St Jude Children's Research Hospital, Memphis · Javid Moslehi, Vanderbilt School of Medicine, Nashville, TN · Gregory Aune, Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX · Eric J. Chow, Fred Hutchinson Cancer Research Center, Seattle, WA · Bonnie Ky, University of Pennsylvania, Philadelphia, PA · Paul C. Nathan, The Hospital for Sick Children, Toronto, Ontario, Canada · Thomas D. Ryan, Cincinnati Children's Hospital Medical Center, Cincinnati, OH · Helena J. van der Pal and Leontien C.M. Kremer, Princess Máxima Center for Pediatric Oncology, Utrecht · and Elvira C. van Dalen and Leontien C.M. Kremer, Emma Children's Hospital/Academic Medical Center, Amsterdam, the Netherlands. ·J Clin Oncol · Pubmed #29874141.

ABSTRACT: Cardiovascular disease (CVD), which includes cardiomyopathy/heart failure, coronary artery disease, stroke, pericardial disease, arrhythmias, and valvular and vascular dysfunction, is a major concern for long-term survivors of childhood cancer. There is clear evidence of increased risk of CVD largely attributable to treatment exposures at a young age, most notably anthracycline chemotherapy and chest-directed radiation therapy, and compounded by traditional cardiovascular risk factors accrued during decades after treatment exposure. Preclinical studies are limited; thus, it is a high priority to understand the pathophysiology of CVD as a result of anticancer treatments, taking into consideration the growing and developing heart. Recently developed personalized risk prediction models can provide decision support before initiation of anticancer therapy or facilitate implementation of screening strategies in at-risk survivors of cancer. Although consensus-based screening guidelines exist for the application of blood and imaging biomarkers of CVD, the most appropriate timing and frequency of these measures in survivors of childhood cancer are not yet fully elucidated. Longitudinal studies are needed to characterize the prognostic importance of subclinical markers of cardiovascular injury on long-term CVD risk. A number of prevention trials across the survivorship spectrum are under way, which include primary prevention (before or during cancer treatment), secondary prevention (after completion of treatment), and integrated approaches to manage modifiable cardiovascular risk factors. Ongoing multidisciplinary collaborations between the oncology, cardiology, primary care, and other subspecialty communities are essential to reduce therapeutic exposures and improve surveillance, prevention, and treatment of CVD in this high-risk population.

21 Review Peripheral Arterial Disease in Women: an Overview of Risk Factor Profile, Clinical Features, and Outcomes. 2018

Jelani, Qurat-Ul-Ain / Petrov, Mikhail / Martinez, Sara C / Holmvang, Lene / Al-Shaibi, Khaled / Alasnag, Mirvat. ·Department of Cardiology, Bridgeport Hospital, Yale New Haven Health, New Haven, CT, USA. · Department of Internal Medicine, Norwalk Hospital, Norwalk, CT, USA. · Division of Cardiology, Providence St. Peter Hospital, Olympia, WA, USA. · Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. · Cardiac Center, King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia. · Cardiac Center, King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia. mirvat@jeddacath.com. ·Curr Atheroscler Rep · Pubmed #29858704.

ABSTRACT: PURPOSE OF REVIEW: Peripheral arterial disease (PAD) is the third most common manifestation of cardiovascular disease (CVD), following coronary artery disease (CAD) and stroke. PAD remains underdiagnosed and under-treated in women. RECENT FINDINGS: Women with PAD experience more atypical symptoms and poorer overall health status. The prevalence of PAD in women increases with age, such that more women than men have PAD after the age of 40 years. There is under-representation of PAD patients in clinical trials in general and women in particular. In this article, we address the lack of women participants in PAD trials. We then present a comprehensive overview of the epidemiology/risk factor profile, clinical features, treatment, and outcomes. PAD is prevalent in women and its global burden is on the rise despite a decline in global age-standardized death rate from CVD. The importance of this issue has been underlined by the American Heart Association's (AHA) "Call to Action" scientific statement on PAD in women. Large-scale campaigns are needed to increase awareness among physicians and the general public. Furthermore, effective treatment strategies must be implemented.

22 Review Stable Coronary Artery Disease: Treatment. 2018

Braun, Michael M / Stevens, William A / Barstow, Craig H. ·Madigan Army Medical Center, Joint Base Lewis-McCord, WA, USA. · Womack Army Medical Center, Fort Bragg, NC, USA. ·Am Fam Physician · Pubmed #29671538.

ABSTRACT: Stable coronary artery disease refers to a reversible supply/demand mismatch related to ischemia, a history of myocardial infarction, or the presence of plaque documented by catheterization or computed tomography angiography. Patients are considered stable if they are asymptomatic or their symptoms are controlled by medications or revascularization. Treatment involves risk factor management, antiplatelet therapy, and antianginal medications. Tobacco cessation, exercise, and weight loss are the most important lifestyle modifications. Treatment of comorbidities such as diabetes mellitus, hyperlipidemia, and hypertension should be optimized to reduce cardiovascular risk. All patients should be started on a statin unless contraindicated. No data support the routine use of monotherapy with nonstatin drugs such as bile acid sequestrants, niacin, ezetimibe, or fibrates. Studies of niacin and fibrates as adjunctive therapy found no improvement in patient outcomes. Aspirin is the mainstay of antiplatelet therapy; clopidogrel is an alternative. Antianginal medications should be added in a stepwise approach beginning with a beta blocker. Calcium channel blockers, nitrates, and ranolazine are used as adjunctive or second-line therapy when beta blockers are ineffective or contraindicated. Select patients may benefit from coronary revascularization with percutaneous coronary intervention or coronary artery bypass grafting.

23 Review Out-of-hospital cardiac arrest: current concepts. 2018

Myat, Aung / Song, Kyoung-Jun / Rea, Thomas. ·Sussex Cardiac Centre, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK; Division of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Brighton, UK. Electronic address: aung.myat@bsuh.nhs.uk. · Department of Emergency Medicine, Seoul National University College of Medicine and Hospital, Seoul, South Korea; Laboratory of Emergency Medical Services, Seoul National University Hospital Biomedical Research Institute, South Korea. · Division of General Internal Medicine, Harborview Medical Centre, University of Washington, Seattle, WA, USA. ·Lancet · Pubmed #29536861.

ABSTRACT: Out-of-hospital cardiac arrest (OHCA) is a leading cause of global mortality. Regional variations in reporting frameworks and survival mean the exact burden of OHCA to public health is unknown. Nevertheless, overall prognosis and neurological outcome are relatively poor following OHCA and have remained almost static for the past three decades. In this Series paper, we explore the aetiology of OHCA. Coronary artery disease remains the predominant cause, but there is a diverse range of other potential cardiac and non-cardiac causes to be aware of. Additionally, we describe how investigators and key stakeholders in resuscitation science have formulated specific Utstein data element domains in an attempt to standardise the definitions and outcomes reported in OHCA research so that management pathways can be improved. Finally, we identify the predictors of survival after OHCA and what primary and secondary prevention strategies can be instigated to mitigate the devastating sequelae of this growing public health issue.

24 Review Pulmonary Atresia With an Intact Ventricular Septum: Preoperative Physiology, Imaging, and Management. 2018

Chikkabyrappa, Sathish M / Loomba, Rohit S / Tretter, Justin T. ·1 Seattle Childrens Hospital, University of Washington, Seattle, WA, USA. · 2 Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. ·Semin Cardiothorac Vasc Anesth · Pubmed #29411679.

ABSTRACT: Pulmonary atresia with intact ventricular septum (PA-IVS) is a rare complex cyanotic congenital heart disease with heterogeneous morphological variation. Prenatal diagnosis allows for developing a safe plan for delivery and postnatal management. While transthoracic echocardiography allows for detailed delineation of the cardiac anatomy, additional imaging modalities such as computed tomography, magnetic resonance imaging, and catheterization may be necessary to further outline features of the cardiac anatomy, specifically coronary artery anatomy. The size of the tricuspid valve and right ventricular cavity as well as the presence of right ventricle-dependent coronary circulation help to dichotomize between biventricular repair versus univentricular palliation or heart transplantation, as well as predicting the expected survival. The delineation and understanding of these features help to dictate both medical and surgical management.

25 Review The State of the Absorb Bioresorbable Scaffold: Consensus From an Expert Panel. 2017

Bangalore, Sripal / Bezerra, Hiram G / Rizik, David G / Armstrong, Ehrin J / Samuels, Bruce / Naidu, Srihari S / Grines, Cindy L / Foster, Malcolm T / Choi, James W / Bertolet, Barry D / Shah, Atman P / Torguson, Rebecca / Avula, Surendra B / Wang, John C / Zidar, James P / Maksoud, Aziz / Kalyanasundaram, Arun / Yakubov, Steven J / Chehab, Bassem M / Spaedy, Anthony J / Potluri, Srini P / Caputo, Ronald P / Kondur, Ashok / Merritt, Robert F / Kaki, Amir / Quesada, Ramon / Parikh, Manish A / Toma, Catalin / Matar, Fadi / DeGregorio, Joseph / Nicholson, William / Batchelor, Wayne / Gollapudi, Raghava / Korngold, Ethan / Sumar, Riyaz / Chrysant, George S / Li, Jun / Gordon, John B / Dave, Rajesh M / Attizzani, Guilherme F / Stys, Tom P / Gigliotti, Osvaldo S / Murphy, Bruce E / Ellis, Stephen G / Waksman, Ron. ·Department of Medicine, New York University School of Medicine, New York, New York. Electronic address: sripalbangalore@gmail.com. · Department of Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio. · Department of Medicine, HonorHealth and the HonorHealth Heart Group, Scottsdale, Arizona. · Department of Medicine, University of Colorado, Denver, Colorado. · Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California. · Department of Medicine, Westchester Medical Center, Valhalla, New York. · Department of Medicine, North Shore University Hospital, Manhasset, New York. · Department of Medicine, Tennova Healthcare, Knoxville, Tennessee. · Department of Medicine, Baylor Heart and Vascular Hospital, Dallas, Texas. · Department of Medicine, North Mississippi Medical Center, Tupelo, Mississippi. · Department of Medicine, University of Chicago, Chicago, Illinois. · Department of Medicine, MedStar Washington Hospital Center, Washington, DC. · Department of Medicine, Advocate Christ Hospital and Medical Center, Oak Lawn, Illinois. · Department of Medicine, MedStar Union Memorial Hospital, Baltimore, Maryland. · Department of Medicine, UNC/Rex Healthcare, Raleigh, North Carolina. · Department of Medicine, Cardiovascular Research Institute of Kansas, Kansas City, Kansas. · Department of Medicine, Seattle Heart and Vascular Institute, Seattle, Washington. · Department of Medicine, OhioHealth, Columbus, Ohio. · Department of Medicine, University of Kansas, Kansas City, Kansas. · Department of Medicine, Missouri Heart Center, Columbia, Missouri. · Department of Medicine, The Heart Hospital Baylor Plano, Plano, Texas. · Department of Medicine, St. Joseph's/Trinity Hospital, Syracuse, New York. · Department of Medicine, DMC Heart Hospital/Wayne State University, Detroit, Michigan. · Department of Medicine, Mercy Hospital and Clinic, Springfield, Missouri. · Department of Medicine, Heart & Vascular Institute, Detroit, Michigan. · Department of Medicine, Miami Cardiac & Vascular Institute, Baptist Health, Miami, Florida. · Department of Medicine, Columbia University Medical Center, New York, New York. · Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. · Department of Medicine, University of South Florida, Tampa, Florida. · Department of Medicine, Englewood Hospital and Medical Center, Englewood, New Jersey. · Department of Medicine, York Hospital, York, Pennsylvania. · Department of Medicine, Tallahassee Memorial Hospital/Florida State University, Tallahassee, Florida. · Department of Medicine, San Diego Cardiac Center, San Diego, California. · Department of Medicine, Providence St. Vincent Medical Center, Portland, Oregon. · Department of Medicine, St. Joseph's Hospital and Medical Center, Phoenix, Arizona. · Department of Medicine, INTEGRIS Baptist Medical Center, Oklahoma City, Oklahoma. · Department of Medicine, Geisinger Holy Spirit, Harrisburg, Pennsylvania. · Department of Medicine, Sanford Health, Sioux Falls, South Dakota. · Department of Medicine, Seton Heart Institute, Austin, Texas. · Department of Medicine, Arkansas Heart Hospital, Little Rock, Arkansas. · Department of Medicine, Cleveland Clinic, Cleveland, Ohio. ·JACC Cardiovasc Interv · Pubmed #29216997.

ABSTRACT: Significant progress has been made in the percutaneous coronary intervention technique from the days of balloon angioplasty to modern-day metallic drug-eluting stents (DES). Although metallic stents solve a temporary problem of acute recoil following balloon angioplasty, they leave behind a permanent problem implicated in very late events (in addition to neoatherosclerosis). BRS were developed as a potential solution to this permanent problem, but the promise of these devices has been tempered by clinical trials showing increased risk of safety outcomes, both early and late. This is not too dissimilar to the challenges seen with first-generation DES in which refinement of deployment technique, prolongation of dual antiplatelet therapy, and technical iteration mitigated excess risk of very late stent thrombosis, making DES the treatment of choice for coronary artery disease. This white paper discusses the factors potentially implicated in the excess risks, including the scaffold consideration and deployment technique, and outlines patient and lesion selection, implantation technique, and dual antiplatelet therapy considerations to potentially mitigate this excess risk with the first-generation thick strut Absorb scaffold (Abbott Vascular, Abbott Park, Illinois). It remains to be seen whether these considerations together with technical iterations will ultimately close the gap between scaffolds and metal stents for short-term events while at the same time preserving options for future revascularization once the scaffold bioresorbs.

Next